A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor malignancies and lymphomas.
Advanced Solid Tumors
DRUG: ABI-011
DLT's and MTD Safety and Toxicity profile, Evaluate PK and PD of ABI-011. Preliminary assessment of tumor response., During Cycle 1, treatment period, End of Study and Follow-Up, approximately up to 2 years
Safety and toxicity profile of repeated dosing of ABI-011, Number of subjects with Adverse Events; laboratory assessments, ECG assessments, opthalmologic assessments, End of study and follow up, approximately up to 2 years|Evaluate plasma PK of ABI-011 on this schedule, End of Study and follow-up, Up to two years|Assess biological activity and PD of ABI-011, End of study and follow-up, approximately 2 years|Make preliminary assessment of tumor response, End of study and follow-up, approximately 2 years|Assess biological activity/exploratory during treatment C1, C2, EOS, End of Study and follow-up, aproximately two years
Dose limiting toxicities (DLT), maximum tolerated dose (MTD)